Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT03997786 Active, not recruiting - Clinical trials for Moderate-to-severe Chronic Plaque Psoriasis

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Start date: January 15, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to <18 years) before initiating the PK study in younger cohort (6 to <12 years)

NCT ID: NCT03992261 Completed - Plaque Psoriasis Clinical Trials

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

Start date: June 14, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.

NCT ID: NCT03991936 Completed - Nail Psoriasis Clinical Trials

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

Start date: March 11, 2020
Phase: Phase 4
Study type: Interventional

This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.

NCT ID: NCT03988439 Recruiting - Psoriasis Clinical Trials

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Start date: March 24, 2021
Phase: Phase 4
Study type: Interventional

This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.

NCT ID: NCT03988335 Completed - Clinical trials for Palmoplantar Pustulosis

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Start date: February 13, 2019
Phase: Phase 2
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

NCT ID: NCT03987763 Recruiting - Psoriasis Clinical Trials

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Start date: October 22, 2019
Phase: Phase 4
Study type: Interventional

This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.

NCT ID: NCT03983980 Completed - Plaque Psoriasis Clinical Trials

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Start date: June 6, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.

NCT ID: NCT03982394 Active, not recruiting - Clinical trials for Chronic Plaque Psoriasis

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

VALUE
Start date: July 1, 2019
Phase:
Study type: Observational

This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.

NCT ID: NCT03979664 Withdrawn - Psoriasis Clinical Trials

Iontophoresis in Psoriasis

Start date: March 2021
Phase: Early Phase 1
Study type: Interventional

Iontophoresis potentially may be a good alternative to improved delivery of corticosteroids. Study Investigators propose to use iontophoresis to increase dexamethasone delivery into thick psoriasis plaques. The primary purpose of this study is to assess whether dexamethasone sodium phosphate iontophoresis is an effective local therapy for psoriasis. The objective of the study is to determine the efficacy of dexamethasone sodium phosphate iontophoresis for psoriasis.

NCT ID: NCT03976622 Not yet recruiting - Psoriasis Clinical Trials

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

INFLAMMAVit
Start date: June 3, 2019
Phase:
Study type: Observational

It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders